Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NPY1R | P25929 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | NPY2R | P49146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7523014 | 0.77 | APOBEC3G (0.35) | APOBEC3GPOLB | |
| SCHEMBL2048982 | 0.76 | CHRM2 (0.48) | APOBEC3GSLC6A4SLC6A2SLC6A3LMNA | |
| SCHEMBL6762797 | 0.76 | FFAR4 (0.49) | APOBEC3GSLC6A2HPGDALDH1A1 | |
| SCHEMBL7674655 | 0.73 | HPGD (0.39) | APOBEC3GLMNAHPGDALDH1A1MAPK1 | |
| SCHEMBL5350956 | 0.73 | HSPA5 (0.38) | APOBEC3GCYP2C9HPGDCYP2C19ALDH1A1 | |
| SCHEMBL3305460 | 0.69 | — | — | |
| SCHEMBL3368806 | 0.69 | — | — | |
| SCHEMBL6963042 | 0.67 | HSPA5 (0.36) | LMNA | |
| SCHEMBL98874 | 0.67 | — | — | |
| SCHEMBL282418 | 0.64 | GABRA1 (0.48) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005011613-A2 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LIPOXYGENASE INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS LLC (US) | 2005-02-10 | — | — | WO | disclosed |